Enabling equitable open access to commercially funded research publications

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Anja Schmidt, Christopher C. Winchester, Catherine Skobe, Diane R. Stothard, Eric Topol Pharmaceutical companies fund much biomedical research, yet many journals restrict open access publishing options for peer-reviewed articles reporting commercially funded research.

Expanded publishing options, such as funder-neutral publishing policies, will help address this inequity. In this Perspective, Christopher Winchester and colleagues discuss how open access options for publishing commercially-funded research are often restricted, examine the consequences of this inequity, and argue for funder-neutral publishing policies.

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · August 27, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.